Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clesrovimab - Merck Sharp & Dohme

Next Previous
X
Search
Drug Profile

Clesrovimab - Merck Sharp & Dohme

Alternative Names: Anti RSV F antibody - Merck Sharp & Dohme; MK-1654

Latest Information Update: 21 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Respiratory syncytial virus infections

Most Recent Events

  • 17 Oct 2024 Adverse events data from a phase III trial in Respiratory syncytial virus infections released by Merck
  • 17 Oct 2024 Efficacy and adverse events data from a phase IIb/III trial in Respiratory syncytial virus infections released by Merck
  • 09 Jul 2024 Merck Sharp & Dohme completes the phase II/III MK-1654-004 trial in Respiratory syncytial virus infections (In infants, In neonates, Prevention) in USA, France, Finland, South Africa, Chile, Colombia, South Korea, Argentina, Canada, Belgium, China, Denmark, Israel, Italy, Malaysia, Mexico, Peru, Poland, Philippines, Romania, Turkey, Thailand, United Kingdom (NCT04767373) (EudraCT2020-002405-26)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top